Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 58, n° 3
pages 395-402 (mars 2008)
Doi : 10.1016/j.jaad.2007.10.645

Subcutaneous efalizumab is not effective in the treatment of alopecia areata

Vera H. Price, MD a, , Maria K. Hordinsky, MD b, Elise A. Olsen, MD c, Janet L. Roberts, MD d, Elaine C. Siegfried, MD e, Elyse S. Rafal, MD f, Neil J. Korman, MD, PhD g, Basel Altrabulsi, MD h, Hoi M. Leung, PhD i, Marvin R. Garovoy, MD j, Ivor Caro, MD k, David A. Whiting, MD l
a Department of Dermatology, University of California, San Francisco, California 
b University of Minnesota, Minneapolis, Minnesota 
c Duke University Medical Center, Durham, North Carolina 
d Northwest Dermatology and Research Center, Portland, Oregon 
e Central Dermatology, St. Louis, Missouri 
f DermResearchCenter of New York, Inc., Stony Brook, New York 
g University Hospitals/Case Medical Center, and the Murdough Family Center for Psoriasis, Cleveland, Ohio 
h Baylor University Medical Center, Dallas, Texas 
l Baylor Hair Research & Treatment Center, Dallas, Texas 
i Xoma, Berkeley, California 
j Arriva Pharmaceuticals, Alameda, California 
k Genentech, Inc., South San Francisco, California 

Reprint requests: Vera H. Price, MD, 1701 Divisadero Street, 3rd Floor, Box 0316, San Francisco, CA 94143-0316.

Alopecia areata (AA) is a T-cell–mediated autoimmune disease. Efalizumab is a T-cell–targeted therapy approved for the treatment of psoriasis.


To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA.


Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The trial consisted of three 12-week periods—a double-blind treatment period, an open-label efalizumab treatment period, and a safety follow-up.


There were no statistical differences between treatment groups in percent hair regrowth, quality-of-life measures, or changes in biologic markers of disease severity after 12 or 24 weeks. In both groups, there was an approximately 8% response rate for hair regrowth (at 12 weeks). Efalizumab was well tolerated.


Numbers were too small for certain analyses.


A 3- to 6-month trial of efalizumab was not effective in promoting hair regrowth in this small cohort of patients with moderate-to-severe AA.

The full text of this article is available in PDF format.

 Presented at the 2006 Society for Investigative Dermatology Annual Meeting, Philadelphia, PA, May 3-6, 2007.
 Supported by Genentech, Inc.
 Disclosures: Dr Price has received grant support and served as an investigator for Xoma and Genentech, Inc. Dr Hordinsky has received grant support and served as an investigator for Astellas and Genentech, Inc. Dr Roberts has received research support and is an investigator for Abbott. Dr Siegfried has been a paid investigator and received honoraria for Genentech, Inc. Dr Rafal has received grant support and served as an investigator for Serono International SA, Amgen, Biogen Idec, and Genentech, Inc. Drs Olsen and Altrabulsi have no conflicts of interest to disclose. Dr Korman has received grant support and honoraria and served as a speaker, consultant, and an advisory board member for Astellas and Novartis; he is an investigator for Novartis. Dr Leung is a stock shareholder and an employee of Xoma. Dr Garovoy is a stock shareholder and was an employee of Xoma, and has been a consultant of Genentech, Inc. Dr Caro is a stock shareholder and an employee of Genentech, Inc. Dr Whiting is an investigator for Xoma and Genentech, Inc.

© 2008  American Academy of Dermatology, Inc.@@#104156@@